Max Werbin-Hardy
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
Peripheral immune cell subsets as potential predictors of benefit from immune checkpoint blockade therapy in small cell lung cancer.
Journal: Frontiers in immunology
Published: February 02, 2026
Molecular and immunological features associated with long-term benefits in metastatic NSCLC patients undergoing immune checkpoint blockade.
Journal: Oncoimmunology
Published: February 24, 2025
Equitable access to oncology clinical trials: harnessing technology to reduce geographic disparities.
Journal: ESMO real world data and digital oncology
Published: December 19, 2023
Comprehensive NGS profiling to enable detection of ALK gene rearrangements and MET amplifications in non-small cell lung cancer.
Journal: Frontiers in oncology
Published: May 19, 2023
MultiCOVID: a multi modal deep learning approach for COVID-19 diagnosis.
Journal: Scientific reports
Published: February 10, 2023
Evaluation of the host immune response assay SeptiCyte RAPID for potential triage of COVID-19 patients.
Journal: Scientific reports
Published: August 12, 2022
Comparison of Different Methods for Defining Hyperprogressive Disease in NSCLC.
Journal: JTO clinical and research reports
Published: July 07, 2020
Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: September 20, 2019
Plasmatic KRAS Kinetics for the Prediction of Treatment Response and Progression in Patients With KRAS-mutant Lung Adenocarcinoma.
Journal: Archivos de bronconeumologia
Published: August 26, 2019
MET Inhibitors in Small Cell Lung Cancer: From the Bench to the Bedside.
Journal: Cancers
Published: August 13, 2019
Real-world data on T-DM1 efficacy - results of a single-center retrospective study of HER2-positive breast cancer patients.
Journal: Scientific reports
Published: February 28, 2019
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer.
Journal: Oncoimmunology
Published: December 19, 2018
Last Updated: 09/26/2026